Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Creative Medical Technology Holdings, In - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CELZ
Nasdaq
2830
www.creativemedicaltechnology.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Creative Medical Technology Holdings, In
Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program
- Feb 11th, 2025 2:25 pm
Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development
- Feb 5th, 2025 1:25 pm
Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain
- Jan 30th, 2025 2:25 pm
Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment
- Nov 13th, 2024 2:00 pm
Creative Medical Technology Holdings Third Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.02 loss in 3Q 2023)
- Nov 10th, 2024 2:19 pm
Creative Medical to sell 418,552 shares at $4.42 in registered direct offering
- Oct 24th, 2024 12:21 pm
Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Oct 23rd, 2024 12:00 pm
Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program
- Jul 24th, 2024 1:00 pm
Here's Why Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) CEO Compensation Is The Least Of Shareholders Concerns
- Jul 12th, 2024 11:00 am
Creative Medical Technology Holdings Provides Corporate Update
- Jul 10th, 2024 12:30 pm
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin
- Jun 24th, 2024 12:30 pm
Creative Medical Technology Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
- Mar 24th, 2024 1:26 pm
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
- Mar 7th, 2024 2:15 pm
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
- Mar 6th, 2024 12:00 pm
Scroll